Our top pick for
Chimerix, Inc is a biotechnology business based in the US. Chimerix shares (CMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Chimerix employs 54 staff and has a trailing 12-month revenue of around USD$5.4 million.
|52-week range||USD$1.19 - USD$11.57|
|50-day moving average||USD$9.4976|
|200-day moving average||USD$4.9444|
|Wall St. target price||USD$13.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.321|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$5.4 million|
|Gross profit TTM||USD$-30,860,000|
|Return on assets TTM||-27.26%|
|Return on equity TTM||-47.48%|
|Market capitalisation||USD$909.1 million|
TTM: trailing 12 months
There are currently 794,294 Chimerix shares held short by investors – that's known as Chimerix's "short interest". This figure is 15% down from 933,964 last month.
There are a few different ways that this level of interest in shorting Chimerix shares can be evaluated.
Chimerix's "short interest ratio" (SIR) is the quantity of Chimerix shares currently shorted divided by the average quantity of Chimerix shares traded daily (recently around 1.1 million). Chimerix's SIR currently stands at 0.75. In other words for every 100,000 Chimerix shares traded daily on the market, roughly 750 shares are currently held short.
However Chimerix's short interest can also be evaluated against the total number of Chimerix shares, or, against the total number of tradable Chimerix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Chimerix's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Chimerix shares in existence, roughly 10 shares are currently held short) or 0.0138% of the tradable shares (for every 100,000 tradable Chimerix shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Chimerix.
Find out more about how you can short Chimerix stock.
We're not expecting Chimerix to pay a dividend over the next 12 months.
Over the last 12 months, Chimerix's shares have ranged in value from as little as $1.19 up to $11.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chimerix's is 1.6462. This would suggest that Chimerix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Everything we know about the Reddit IPO, plus information on how to buy in.
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
Everything we know about the Procore IPO, plus information on how to buy in.
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Bukalapak IPO, plus information on how to buy in.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.